FOR IMMEDIATE RELEASE
December 20, 2008
Joint Presentation from Novartis and Human Genome Sciences at GTCbio’s 5th Anti-Infectives Partnering & Deal-Making
Summit (March 5-7, 2008,
Philadelphia, PA)
MONROVIA, CA – Mark Coflin, Global Executive Director of IDTI Alliance Mgmt at Novartis and Margery B. Fischbein, Vice President of Business Development & Strategic Planning at Human Genome Sciences will give a joint presentation at GTCbio’s 5th Anti-Infectives Partnering & Deal-Making Summit taking place on March 5-7 2008 in
Philadelphia, PA.
They will present on “The Novartis / Human Genome Sciences Albuferon Alliance – Key Success Factors in Driving Successful Biotech / Big Pharma Alliances.†Their presentation highlights
- Motivations for Pharma-Biotech Collaborations
- Novartis and Human Genome Sciences Business Development Drivers
- Overview of Human Genome Sciences and Novartis Pipeline
- Our Shared Collaboration Philosophy and Deal Structure
- Alliance Challenges and Synergies
- Best Practices and Key Lessons Learned
The conference also features presentations from AstraZeneca, Baselia, Biota, Boehringer Ingelheim, Eli Lilly and Company, Global Alliance for TB Drug Development, GlaxoSmithKline, Merck, Wyeth and many more. The full agenda is available online at www.gtcbio.com.
The 5th Anti-Infectives Partnering & Deal Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry.
This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry. For more information, please visit www.gtcbio.com.ABOUT GTCbio GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.Contact: GTCBIO
(626)
256-6405,
(626)
256-6460 fax, [email protected]
